Author
Listed:
- Johannes Zuegg
(Institute for Molecular Bioscience, The University of Queensland
Alchemia Ltd)
- Craig Muldoon
(Alchemia Ltd)
- George Adamson
(Alchemia Ltd)
- Declan McKeveney
(Alchemia Ltd)
- Giang Le Thanh
(Alchemia Ltd)
- Rajaratnam Premraj
(Alchemia Ltd)
- Bernd Becker
(Alchemia Ltd)
- Mu Cheng
(Institute for Molecular Bioscience, The University of Queensland)
- Alysha G. Elliott
(Institute for Molecular Bioscience, The University of Queensland)
- Johnny X. Huang
(Institute for Molecular Bioscience, The University of Queensland)
- Mark S. Butler
(Institute for Molecular Bioscience, The University of Queensland)
- Megha Bajaj
(Institute for Molecular Bioscience, The University of Queensland)
- Joachim Seifert
(Alchemia Ltd)
- Latika Singh
(Alchemia Ltd)
- Nicola F. Galley
(School of Life Science, University of Warwick)
- David I. Roper
(School of Life Science, University of Warwick)
- Adrian J. Lloyd
(School of Life Science, University of Warwick)
- Christopher G. Dowson
(School of Life Science, University of Warwick)
- Ting-Jen Cheng
(Genomics Research Center, Academia Sinica)
- Wei-Chieh Cheng
(Genomics Research Center, Academia Sinica)
- Dieter Demon
(Faculty of Veterinary Medicine, Laboratory of Biochemistry, Ghent University)
- Evelyne Meyer
(Faculty of Veterinary Medicine, Laboratory of Biochemistry, Ghent University)
- Wim Meutermans
(Alchemia Ltd)
- Matthew A. Cooper
(Institute for Molecular Bioscience, The University of Queensland)
Abstract
The rapid rise of multi-drug-resistant bacteria is a global healthcare crisis, and new antibiotics are urgently required, especially those with modes of action that have low-resistance potential. One promising lead is the liposaccharide antibiotic moenomycin that inhibits bacterial glycosyltransferases, which are essential for peptidoglycan polymerization, while displaying a low rate of resistance. Unfortunately, the lipophilicity of moenomycin leads to unfavourable pharmacokinetic properties that render it unsuitable for systemic administration. In this study, we show that using moenomycin and other glycosyltransferase inhibitors as templates, we were able to synthesize compound libraries based on novel pyranose scaffold chemistry, with moenomycin-like activity, but with improved drug-like properties. The novel compounds exhibit in vitro inhibition comparable to moenomycin, with low toxicity and good efficacy in several in vivo models of infection. This approach based on non-planar carbohydrate scaffolds provides a new opportunity to develop new antibiotics with low propensity for resistance induction.
Suggested Citation
Johannes Zuegg & Craig Muldoon & George Adamson & Declan McKeveney & Giang Le Thanh & Rajaratnam Premraj & Bernd Becker & Mu Cheng & Alysha G. Elliott & Johnny X. Huang & Mark S. Butler & Megha Bajaj , 2015.
"Carbohydrate scaffolds as glycosyltransferase inhibitors with in vivo antibacterial activity,"
Nature Communications, Nature, vol. 6(1), pages 1-11, November.
Handle:
RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms8719
DOI: 10.1038/ncomms8719
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms8719. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.